Report Content
Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.2.1 North America
1.2.2 Europe
1.2.3 Asia Pacific
1.2.4 Latin America
1.2.5 Middle East and Africa
1.3 Forecast calculations
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Liquid biopsy industry 3600 synopsis, 2016 – 2027 (USD Million)
2.1.1 Business trends
2.1.2 Biomarkers trends
2.1.3 Product trends
2.1.4 Application trends
2.1.5 Regional trends
Chapter 3 Liquid Biopsy Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2016 – 2027 (USD Million)
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Continuous technological advancements in cancer diagnostics
3.3.1.2 Increasing preference for non-invasive disease diagnosis
3.3.1.3 Growing prevalence of cancer worldwide
3.3.1.4 Rising awareness regarding early disease diagnosis
3.3.2 Industry pitfalls & challenges
3.3.2.1 Stringent regulatory framework
3.3.2.2 Lack of skilled professionals
3.4 Growth potential analysis
3.4.1 By biomarkers
3.4.2 By product
3.4.3 By application
3.5 COVID-19 impact analysis
3.6 Service provider landscape
3.7 Porter’s analysis
3.8 Competitive landscape, 2020
3.9 PESTEL analysis
Chapter 4 Liquid Biopsy Market, By Biomarkers
4.1 Key segment trends
4.2 Circulating tumor cells (CTC)
4.2.1 Market size, by region, 2016 – 2027 (USD Million)
4.3 Circulating tumor DNA (ctDNA)
4.3.1 Market size, by region, 2016 – 2027 (USD Million)
4.4 Others
4.4.1 Market size, by region, 2016 – 2027 (USD Million)
Chapter 5 Liquid Biopsy Market, By Product
5.1 Key segment trends
5.2 Kits & reagents
5.2.1 Market size, by region, 2016 – 2027 (USD Million)
5.3 Assay & panels
5.3.1 Market size, by region, 2016 – 2027 (USD Million)
5.4 Others
5.4.1 Market size, by region, 2016 – 2027 (USD Million)
Chapter 6 Liquid Biopsy Market, By Application
6.1 Key segment trends
6.2 Lung cancer
6.2.1 Market size, by region, 2016 – 2027 (USD Million)
6.3 Breast cancer
6.3.1 Market size, by region, 2016 – 2027 (USD Million)
6.4 Colorectal cancer
6.4.1 Market size, by region, 2016 – 2027 (USD Million)
6.5 Prostate cancer
6.5.1 Market size, by region, 2016 – 2027 (USD Million)
6.6 Others
6.6.1 Market size, by region, 2016 – 2027 (USD Million)
Chapter 7 Liquid Biopsy Market, By Region
7.1 Key regional trends
7.2 North America
7.2.1 Market size by country, 2016 – 2027 (USD Million)
7.2.2 Market size by biomarkers, 2016 – 2027 (USD Million)
7.2.3 Market size by product, 2016 – 2027 (USD Million)
7.2.4 Market size by application, 2016 – 2027 (USD Million)
7.2.5 U.S.
7.2.5.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.2.5.2 Market size by product, 2016 – 2027 (USD Million)
7.2.5.3 Market size by application, 2016 – 2027 (USD Million)
7.2.6 Canada
7.2.6.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.2.6.2 Market size by product, 2016 – 2027 (USD Million)
7.2.6.3 Market size by application, 2016 – 2027 (USD Million)
7.3 Europe
7.3.1 Market size by country, 2016 – 2027 (USD Million)
7.3.2 Market size by biomarkers, 2016 – 2027 (USD Million)
7.3.3 Market size by product, 2016 – 2027 (USD Million)
7.3.4 Market size by application, 2016 – 2027 (USD Million)
7.3.5 Germany
7.3.5.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.3.5.2 Market size by product, 2016 – 2027 (USD Million)
7.3.5.3 Market size by application, 2016 – 2027 (USD Million)
7.3.6 UK
7.3.6.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.3.6.2 Market size by product, 2016 – 2027 (USD Million)
7.3.6.3 Market size by application, 2016 – 2027 (USD Million)
7.3.7 France
7.3.7.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.3.7.2 Market size by product, 2016 – 2027 (USD Million)
7.3.7.3 Market size by application, 2016 – 2027 (USD Million)
7.3.8 Italy
7.3.8.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.3.8.2 Market size by product, 2016 – 2027 (USD Million)
7.3.8.3 Market size by application, 2016 – 2027 (USD Million)
7.3.9 Spain
7.3.9.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.3.9.2 Market size by product, 2016 – 2027 (USD Million)
7.3.9.3 Market size by application, 2016 – 2027 (USD Million)
7.4 Asia Pacific
7.4.1 Market size by country, 2016 – 2027 (USD Million)
7.4.2 Market size by biomarkers, 2016 – 2027 (USD Million)
7.4.3 Market size by product, 2016 – 2027 (USD Million)
7.4.4 Market size by application, 2016 – 2027 (USD Million)
7.4.5 Japan
7.4.5.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.4.5.2 Market size by product, 2016 – 2027 (USD Million)
7.4.5.3 Market size by application, 2016 – 2027 (USD Million)
7.4.6 China
7.4.6.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.4.6.2 Market size by product, 2016 – 2027 (USD Million)
7.4.6.3 Market size by application, 2016 – 2027 (USD Million)
7.4.7 India
7.4.7.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.4.7.2 Market size by product, 2016 – 2027 (USD Million)
7.4.7.3 Market size by application, 2016 – 2027 (USD Million)
7.5 Latin America
7.5.1 Market size by country, 2016 – 2027 (USD Million)
7.5.2 Market size by biomarkers, 2016 – 2027 (USD Million)
7.5.3 Market size by product, 2016 – 2027 (USD Million)
7.5.4 Market size by application, 2016 – 2027 (USD Million)
7.5.5 Brazil
7.5.5.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.5.5.2 Market size by product, 2016 – 2027 (USD Million)
7.5.5.3 Market size by application, 2016 – 2027 (USD Million)
7.5.6 Mexico
7.5.6.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.5.6.2 Market size by product, 2016 – 2027 (USD Million)
7.5.6.3 Market size by application, 2016 – 2027 (USD Million)
7.6 Middle East & Africa
7.6.1 Market size by country, 2016 – 2027 (USD Million)
7.6.2 Market size by biomarkers, 2016 – 2027 (USD Million)
7.6.3 Market size by product, 2016 – 2027 (USD Million)
7.6.4 Market size by application, 2016 – 2027 (USD Million)
7.6.5 South Africa
7.6.5.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.6.5.2 Market size by product, 2016 – 2027 (USD Million)
7.6.5.3 Market size by application, 2016 – 2027 (USD Million)
7.6.6 Saudi Arabia
7.6.6.1 Market size by biomarkers, 2016 – 2027 (USD Million)
7.6.6.2 Market size by product, 2016 – 2027 (USD Million)
7.6.6.3 Market size by application, 2016 – 2027 (USD Million)
Chapter 8 Company Profiles
8.1 Competitive dashboard, 2020
8.2 QIAGEN
8.2.1 Business overview
8.2.2 Financial data
8.2.3 Product landscape
8.2.4 Strategic outlook
8.2.5 SWOT analysis
8.3 BIOCEPT, Inc.
8.3.1 Business overview
8.3.2 Financial data
8.3.3 Product landscape
8.3.4 Strategic outlook
8.3.5 SWOT analysis
8.4 Myriad Genetics, Inc.
8.4.1 Business overview
8.4.2 Financial data
8.4.3 Product landscape
8.4.4 Strategic outlook
8.4.5 SWOT analysis
8.5 Guardant Health, Inc.
8.5.1 Business overview
8.5.2 Financial data
8.5.3 Product landscape
8.5.4 Strategic outlook
8.5.5 SWOT analysis
8.6 Illumina, Inc.
8.6.1 Business overview
8.6.2 Financial data
8.6.3 Product landscape
8.6.4 Strategic outlook
8.6.5 SWOT analysis
8.7 F. Hoffmann La Roche Ltd.
8.7.1 Business overview
8.7.2 Financial data
8.7.3 Product landscape
8.7.4 Strategic outlook
8.7.5 SWOT analysis
8.8 Thermo Fisher Scientific, Inc.
8.8.1 Business overview
8.8.2 Financial data
8.8.3 Product landscape
8.8.4 Strategic outlook
8.8.5 SWOT analysis
8.9 Angle plc.
8.9.1 Business overview
8.9.2 Financial data
8.9.3 Product landscape
8.9.4 Strategic outlook
8.9.5 SWOT analysis
8.10 Oncimmune
8.10.1 Business overview
8.10.2 Financial data
8.10.3 Product landscape
8.10.4 Strategic outlook
8.10.5 SWOT analysis
8.11 EPIGENOMICS AG
8.11.1 Business overview
8.11.2 Financial data
8.11.3 Product landscape
8.11.4 Strategic outlook
8.11.5 SWOT analysis
8.12 Lucene Health Inc.
8.12.1 Business overview
8.12.2 Financial data
8.12.3 Product landscape
8.12.4 Strategic outlook
8.12.5 SWOT analysis
8.13 Freenome Holdings, Inc.
8.13.1 Business overview
8.13.2 Financial data
8.13.3 Product landscape
8.13.4 Strategic outlook
8.13.5 SWOT analysis
8.14 MDxHealth SA
8.14.1 Business overview
8.14.2 Financial data
8.14.3 Product landscape
8.14.4 Strategic outlook
8.14.5 SWOT analysis
8.15 Bio RAD Laboratories Inc.
8.15.1 Business overview
8.15.2 Financial data
8.15.3 Product landscape
8.15.4 Strategic outlook
8.15.5 SWOT analysis
8.16 Menarini Silicon Biosystems
8.16.1 Business overview
8.16.2 Financial data
8.16.3 Product landscape
8.16.4 Strategic outlook
8.16.5 SWOT analysis
